Touting nine-figure deal package, Pfizer extends collaboration with AI partner
More than two years after Pfizer tied the knot with machine learning firm CytoReason in an AI-focused deal, the two companies have agreed to keep the partnership alive for at least five more years.
CytoReason, a Big Pharma partner in its own right with Sanofi, Merck and Roche as clients, announced the extension on Tuesday, elaborating more on the company’s partnership with the Big Pharma giant that has been ongoing since before Pfizer’s historic Covid-19 vaccine Comirnaty.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.